Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Eberswalde – page 113

1 792 clinical trials in Eberswalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Eberswalde at a glance
1 792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 792 trials in Eberswalde

Open in trial search

B-cell lymphoma+2

Not recruiting

Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:GWT-Tud GmbH

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Asthma

Not recruiting

Study on the Effectiveness and Safety of AZD4604 for Adults with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Londamocitinib xinafoate
  • Sponsor:AstraZeneca AB

Study on the Early Use of Risdiplam for Children with Spinal Muscular Atrophy After Gene Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Risdiplam
  • Sponsor:F. Hoffmann-La Roche AG

Arteriosclerosis

Not recruiting

Study on DFV890 and MAS825 for Reducing Inflammation in Adults with Coronary Heart Disease and Clonal Hematopoiesis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Arumakimig
  • Sponsor:Novartis Pharma AG

Multiple sclerosis+2

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Study on Nipocalimab for Adults with Warm Autoimmune Hemolytic Anemia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Study on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Novartis Pharma AG

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Pustular psoriasis

Not recruiting

Study on Long-Term Spesolimab Treatment for Patients with Generalized Pustular Psoriasis from Previous Trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Eberswalde

What the registry says about research in the country

01 Hematologic Oncology

Clinical research focusing on Diffuse Large B-Cell Lymphoma (DLBCL) and its various subtypes, evaluating innovative combination therapies for elderly patients.

  • Treatment optimization for older adults
  • B-cell lymphoma variants
  • Targeted therapy combinations

The study explores the effectiveness of combining acalabrutinib with standard lymphoma treatments to improve outcomes in patients over 60 and 80 years of age.

02 Specialized Lymphoma Research

Investigation of multiple B-cell lymphoma subtypes, including rare variants such as primary cutaneous, intravascular, and mediastinal forms.

  • Novel therapeutic approaches
  • Rare lymphoma variants
  • Treatment response assessment

Research aims to enhance progression-free survival through targeted therapeutic strategies.

03 Personalized Medicine

Advancing treatment protocols for elderly lymphoma patients with focus on reduced-intensity therapy combinations.

  • Age-adapted treatments
  • Quality of life considerations
  • Therapeutic efficacy

Studies evaluate modified treatment regimens designed specifically for older adults who cannot tolerate standard intensive therapies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.